Application of liquid biopsy in early screening and recurrence prediction of hepatocellular carcinoma.
10.3760/cma.j.cn501113-20220627-00352
- Author:
Xin HAO
1
;
Shu Yun DENG
1
;
Kun Yuan WANG
1
;
Lei CHEN
2
;
Jin Lin HOU
1
;
Wei Wei WEI
3
;
Jinzhang CHEN
1
Author Information
1. Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Guangdong Provincial Institute of Liver Diseases, Guangzhou 510515, China.
2. National Center for liver Cancer/Eastern Hepatobiliary Surgery Hospital, Navy Medical University, Shanghai 200433,China.
3. Medical Affairs Department, Berry Oncology Clinical Laboratory, Fuzhou 350200, China.
- Publication Type:Journal Article
- MeSH:
Biomarkers;
Carcinoma, Hepatocellular/pathology*;
Humans;
Liquid Biopsy;
Liver Neoplasms/pathology*;
Mass Screening;
Neoplasm Recurrence, Local
- From:
Chinese Journal of Hepatology
2022;30(8):814-819
- CountryChina
- Language:Chinese
-
Abstract:
The incidence and mortality of HCC in China account for approximately 50% of all cases worldwide. Low early diagnosis rate and high postoperative recurrence rate are two major causes for poor 5-year survival rate of HCC patients in China. At present, multiple problems such as low performance and compliance of screening technology and lack of effective markers for predicting postoperative recurrence, remain to be resolved. Due to the simplicity and accuracy, new molecular markers, such as liquid biopsy, are expected to serve as supplementary tools to traditional screening and early warning approaches, thereby realizing early detection and accurate treatment of HCC. In this article, research progress upon the clinical application of liquid biopsy in early screening and prediction of postoperative recurrence of HCC was reviewed, and prospects the future research.
